News blog

Reimagining disease by mining patients’ molecular data

In 2011, a patient newly diagnosed with type II diabetes will likely receive the same drug, metformin, that was first approved in 1957. What’s more – in the absence of information on the underlying molecular mechanisms of her particular case – that patient will likely end up taking a one-size-fits-all pill rather than a drug tailored for her unique disease subtype. Nor are there tests available that would allow her family members to pinpoint their genetic-based risk for the disease. 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE